{
    "clinical_study": {
        "@rank": "63860", 
        "arm_group": [
            {
                "arm_group_label": "Callmax cream", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "."
            }
        ], 
        "brief_summary": {
            "textblock": "Uraemic pruritus (UP) remains a frequent and distressing problem in patients with advanced\n      chronic kidney disease (CKD) and end-stage renal disease (ESRD).\n\n      Calmmax is a new topical cream that was introduced recently by Calmmax Pharma, an Israeli\n      pharmaceutical company developed a topical cream based on active plant extracts  for\n      treatment of  skin inflammation. We intend to conduct a prospective, double blind, placebo\n      controlled, randomized trial that will assess the therapeutic effect of Calmmax cream on UP\n      in a cohort of CKD and ESRD patients."
        }, 
        "brief_title": "Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Calmmax Cream on UP in CKD Patients.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. History of pruritus of >8 weeks duration.\n\n          2. Severity score of pruritus \u22655 as defined by VAS\n\n          3. Discontinuation of any medication with presumed antipruritic effects at least 1 week\n             before the study (including Calmmax cream)\n\n          4. Negative pregnancy test result for all participating women of childbearing age;\n\n        Exclusion Criteria:\n\n          1. Known allergy to Calmmax cream\n\n          2. Any acute illness\n\n          3. Liver cirrhosis\n\n          4. Active dermatological disorder other than UP\n\n          5. Decompensated heart failure\n\n          6. Inability to give informed consent\n\n          7. Known poor adherence to medical recommendations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032537", 
            "org_study_id": "Shavit.ctil"
        }, 
        "intervention": [
            {
                "arm_group_label": "Callmax cream", 
                "description": "Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.", 
                "intervention_name": "Callmax cream application over affected skin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "callmax cream", 
            "uremic pruritus"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "email": "islotki@szmc.org.il", 
                "last_name": "Itzchak Slotki, Dr", 
                "phone": "97226555111"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "91031"
                }, 
                "name": "Shaare Zedek Medical Center"
            }, 
            "investigator": {
                "last_name": "Linda Shavit, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "lshavit@szmc.org.il", 
            "last_name": "Linda Shavit, Dr", 
            "phone": "97226555111"
        }, 
        "overall_official": {
            "affiliation": "Shaare Zedek Medical Center", 
            "last_name": "Itzchak Slotki, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement of UP measured by reduction of VAS by more than 50 percent from baseline score", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032537"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaare Zedek Medical Center", 
            "investigator_full_name": "Linda Shavit", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "quality of life assessed by questionnaire", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Shaare Zedek Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shaare Zedek Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}